Search clinical trials for: XPro1595

Total 5 results

Inmune Bio, Inc.
Alzheimer's Association

Completed

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

Alzheimer Disease

Australia
Inmune Bio, Inc.

Recruiting

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

Australia, Canada
Inmune Bio, Inc.

Recruiting

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (MINDFuL)

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment

Australia, Canada, United Kingdom, Poland
Inmune Bio, Inc.

Withdrawn

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurodegenerative Diseases | Dementia | Mild Cognitive Impairment (MCI) | Alzheimer Disease | Tauopathies
Inmune Bio, Inc.

Terminated

INB03 for the Treatment of Pulmonary Complications From COVID-19

COVID-19

United States

3

Subscribe